Preclinical Incorporation Dosimetry of [
Animals
Bone Marrow
/ drug effects
Fluorine Radioisotopes
Monocarboxylic Acid Transporters
/ antagonists & inhibitors
Neoplasms
/ diagnostic imaging
Positron Emission Tomography Computed Tomography
/ methods
Radiometry
/ methods
Radiopharmaceuticals
/ chemical synthesis
Stomach
/ drug effects
Swine
Symporters
/ antagonists & inhibitors
Tissue Distribution
/ drug effects
Tomography, X-Ray Computed
/ methods
Urinary Bladder
/ drug effects
MCT1/MCT4 lactate transporter inhibitor
OLINDA
[18F]FACH
image-based internal dosimetry
preclinical radiopharmaceutical dosimetry
radiation safety
Journal
Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009
Informations de publication
Date de publication:
26 Apr 2020
26 Apr 2020
Historique:
received:
28
03
2020
revised:
18
04
2020
accepted:
20
04
2020
entrez:
3
5
2020
pubmed:
3
5
2020
medline:
20
2
2021
Statut:
epublish
Résumé
Overexpression of monocarboxylate transporters (MCTs) has been shown for a variety of human cancers (e.g., colon, brain, breast, and kidney) and inhibition resulted in intracellular lactate accumulation, acidosis, and cell death. Thus, MCTs are promising targets to investigate tumor cancer metabolism with positron emission tomography (PET). Here, the organ doses (ODs) and the effective dose (ED) of the first
Identifiants
pubmed: 32357571
pii: molecules25092024
doi: 10.3390/molecules25092024
pmc: PMC7248880
pii:
doi:
Substances chimiques
Fluorine Radioisotopes
0
Monocarboxylic Acid Transporters
0
Radiopharmaceuticals
0
Symporters
0
monocarboxylate transport protein 1
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Strahlenschutzseminar in Thueringen e.V.
ID : F2015-06
Références
Am J Physiol Renal Physiol. 2010 Jul;299(1):F141-54
pubmed: 20392797
Physiol Res. 2015;64(4):513-22
pubmed: 25470525
J Nucl Med. 2007 Dec;48(12):2046-55
pubmed: 18056334
Mol Aspects Med. 2013 Apr-Jun;34(2-3):337-49
pubmed: 23506875
J Nucl Med. 2014 Nov;55(11):1885-92
pubmed: 25286922
Mol Pharm. 2006 Nov-Dec;3(6):675-85
pubmed: 17140255
Nat Rev Cancer. 2010 Apr;10(4):267-77
pubmed: 20300106
Nat Rev Cancer. 2011 May;11(5):325-37
pubmed: 21508971
Clin Pharmacol Ther. 2016 Nov;100(5):454-463
pubmed: 27351344
Crit Rev Eukaryot Gene Expr. 2011;21(1):13-28
pubmed: 21967330
Pharmaceuticals (Basel). 2019 Jan 23;12(1):
pubmed: 30678034
Am J Cancer Res. 2018 Oct 01;8(10):1967-1976
pubmed: 30416849
Science. 1956 Feb 24;123(3191):309-14
pubmed: 13298683
Cancer Res. 2017 Oct 15;77(20):5591-5601
pubmed: 28827372
Mol Pharmacol. 2006 Dec;70(6):2108-15
pubmed: 17000864
Bioorg Med Chem Lett. 2017 Nov 1;27(21):4893-4897
pubmed: 28951078
Int J Clin Oncol. 2006 Aug;11(4):286-96
pubmed: 16937302
Comp Biochem Physiol A Mol Integr Physiol. 2005 May;141(1):29-34
pubmed: 15953554
Cancer Cell. 2012 Mar 20;21(3):297-308
pubmed: 22439925
Oncotarget. 2017 Apr 11;8(15):24415-24428
pubmed: 28107190
ACS Med Chem Lett. 2015 Mar 19;6(5):558-61
pubmed: 26005533
Eur J Nucl Med Mol Imaging. 2013 Oct;40(11):1781-3
pubmed: 23868334
EJNMMI Phys. 2016 Dec;3(1):25
pubmed: 27770429
Sci Rep. 2019 Dec 11;9(1):18890
pubmed: 31827199
J Membr Biol. 1982;70(2):89-103
pubmed: 6764785
Vet J. 2007 Jul;174(1):122-8
pubmed: 16901736
Mol Metab. 2020 Mar;33:48-66
pubmed: 31395464
Molecules. 2016 Sep 01;21(9):
pubmed: 27598110
J Neurol Sci. 1990 Nov;99(2-3):339-48
pubmed: 2086732
J Bioenerg Biomembr. 2012 Feb;44(1):127-39
pubmed: 22407107
Biochem J. 1990 Aug 1;269(3):827-9
pubmed: 2390070
J Nucl Med. 2018 Jan;59(1):154-160
pubmed: 28887400
J Labelled Comp Radiopharm. 2019 Jun 30;62(8):411-424
pubmed: 31017677